Daiichi Sankyo is the second largest pharma company in Japan, developing small molecules & biologics for various diseases and was came into existence in 2005, through the merger of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd.
| Molecule | Target | Phase | Indication | NCT Number | Mol Type |
|---|---|---|---|---|---|
| Pirtobrutinib / LOXO-305 | BTK | III | Mantle-Cell Lymphoma | NCT04662255 | Small Molecule |
| III | Chronic Lymphocytic Leukemia | NCT04666038 | |||
| Small Lymphocytic Lymphoma | |||||
| LY3484356 | SERD | I | Metastatic Breast Cancer | NCT04188548 | Small Molecule |
| Endometrial Cancer | |||||
| LY3475070 | CD73 | I | Advanced Cancer | NCT04148937 | Small Molecule |
| LY3295668 | Aur A Kinase | I | Neuroblastoma | NCT04106219 | Small Molecule |
| LY3410738 | IDH1 | I | Advanced Solid Tumors | NCT04521686 | Small Molecule |
| Advanced Hematologic Malignancies | NCT04603001 |
Daiichi Sankyo Active Oncology Pipeline Drug Description
- Teserpaturev is an oncolytic herpes simplex virus type 1 (HSV-1), which has triple mutations in the viral genome that replicate selectively in cancer cells and enhance the induction of antitumor immune response while maintaining high safety.
- Teserpaturev is co-developed by Daiichi Sankyo and Dr. Tomoki Todo, Professor at the Institute of Medical Science, University of Tokyo.
- U3-1402 is a novel HER3-antibody-drug conjugate (ADC) composed of the HER3 antibody patritumab and a novel topoisomerase I inhibitor, for the treatment of Colorectal Cancer.
- Turalio / Pexidartinib is a small-molecule receptor tyrosine kinase (RTK) inhibitor of proto-oncogene receptor tyrosine kinase (KIT), colony-stimulating factor-1 receptor (CSF1R) and FMS-like tyrosine kinase 3 (FLT3), with antineoplastic activity.
- DS-1001b is an oral selective inhibitor of mutant IDH1 R132X that was designed to penetrate the blood-brain barrier.
- DS-1055 is a GARP directed immuno-oncology therapy, in patients with advanced or metastatic solid tumors who have progressed on standard treatments including checkpoint inhibitors. GARP is highly expressed on activated regulatory T cells (Tregs) and contributes to their immunosuppressive activity.
- DS-6000 is a CDH6 directed antibody drug conjugate (ADC), in patients with advanced renal cell carcinoma or ovarian cancer with disease progression following standard treatment.
- CDH6 overexpression is associated with tumor growth and proliferation and has been correlated with poor prognosis in renal cell carcinoma.
- DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the oncology pipeline of Daiichi Sankyo to enter clinical development.
- DS-7300, a B7-H3 (B7 homologue 3) targeting antibody-drug conjugate (ADC), is designed using Daiichi Sankyo’s proprietary DXd technology, and comprised of a humanized anti-B7-H3 monoclonal antibody, attached to a novel topoisomerase I inhibitor payload by a tetrapeptide-based linker.
- Designed utilizing Daiichi Sankyo’s proprietary DXd ADC technology, DS-6157 is comprised of a humanized anti-GPR20 monoclonal antibody, which is attached to a novel topoisomerase I inhibitor payload by a tetrapeptide-based linker.
Page 2 of 2
